BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/30/2025 6:31:46 AM | Browse: 123 | Download: 0
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Editorial |
Article Title |
Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy
|
Manuscript Source |
Invited Manuscript |
All Author List |
Vasily Isakov and Alexei Goncharov |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Ministry of Science and Higher Education of the Russian Federation |
FGMF-2025-0003 |
|
Corresponding Author |
Vasily Isakov, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, 21 Kashirskoe Shosse, Moscow 115446, Russia. vasily.isakov@gmail.com |
Key Words |
Helicobacter pylori; First-line treatment; Vonoprazan; Triple therapy; Proton pump inhibitors |
Core Tip |
This editorial highlights a pivotal multicenter randomized controlled trial from China demonstrating that vonoprazan (VPZ)-based triple therapy achieves superior or non-inferior Helicobacter pylori eradication rates compared to standard bismuth quadruple regimens, even in high clarithromycin resistance regions. The 10-day VPZ-amoxicillin-clarithromycin regimen exceeded 90% per-protocol efficacy with fewer adverse events, offering a simplified, well-tolerated alternative aligned with global treatment goals. These findings underscore a shift in empirical first-line therapy and support the integration of VPZ into updated regional and international guidelines. |
Citation |
Isakov V, Goncharov A. Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy. World J Gastroenterol 2025; In press |
 |
Received |
|
2025-07-23 02:03 |
 |
Peer-Review Started |
|
2025-07-23 02:04 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-08-25 07:52 |
 |
Revised |
|
2025-08-25 14:05 |
 |
Second Decision |
|
2025-09-30 02:46 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-09-30 06:31 |
 |
Articles in Press |
|
2025-09-30 06:31 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345